Finance

Lists
TEVJF:OTCMKTS
Teva Pharmaceutical Industries Limited..
$28.40
0.00%
(0.00) 1D
Jul 21, 3:18:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TEVJF...
Mkt. cap
40.26B
Avg. vol.
10.00
Volume
0.00
52-wk high
$37.00
52-wk low
$14.32
Beta
1.04
Shares outstanding
1.16B
No. of employees
32K
Mkt. cap
40.26B
Avg. vol.
10.00
Volume
0.00
52-wk high
$37.00
52-wk low
$14.32
Beta
1.04
Shares outstanding
1.16B
No. of employees
32K
News stories
From sources across the web
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Limited..
CEORichard Francis
Employees32K
FoundedFeb 13, 1944
Headquarters-
SectorPharmaceutical industry
Websiteteva.co.il
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
4.48B
4.71B
3.98B
4.14B
Cost of goods sold
2.18B
2.06B
2.01B
1.99B
Cost of revenue
2.18B
2.06B
2.01B
1.99B
Research and development expenses
256.00M
267.00M
222.00M
970.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
973.00M
1.12B
1.00B
1.03B
Operating expense
1.24B
1.37B
1.21B
1.99B
Total operating expenses
3.41B
3.43B
3.22B
3.98B
Operating income
1.07B
1.28B
763.00M
167.00M
Other non operating income
-27.00M
-
-13.00M
-69.00M
EBT including unusual items
648.00M
90.00M
436.00M
-455.00M
EBT excluding unusual items
832.00M
1.08B
547.00M
-57.00M
Income tax expense
214.00M
-390.00M
67.00M
121.00M
Effective tax rate
33.02%
-433.33%
15.37%
-26.59%
Other operating expenses
9.00M
-17.00M
-14.00M
-18.00M
Net income
433.00M
480.00M
369.00M
-576.00M
Net profit margin
9.67%
10.19%
9.27%
-13.91%
Earnings per share
0.78
0.96
0.53
0.02
Interest and investment income
-
92.00M
-
-
Interest expense
-205.00M
-280.00M
-191.00M
-186.00M
Net interest expenses
-205.00M
-188.00M
-191.00M
-186.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.32B
1.54B
1.00B
408.00M
Gain or loss from assets sale
-
-
-8.00M
-12.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps